This is the third in our series of regulatory updates on the EU Artificial Intelligence Act (AIA). Since more than one month has passed since the law’s approval, we are providing this article ahead of the AIA’s publication in the Official Journal of European Union (OJEU).
Background
On May 21 2024, the EU AIA was approved and given the final green light by the EU Council. The AIA establishes requirements for compliance of AI systems and general-purpose AI (GPAI) models made available or put into service in the EU market. In our first regulatory update we discussed scope, classification, conformity and economic operators. Our second regulatory update went on to discuss best practices, enforcement and innovation. In this update we focus specifically on the penalties and timelines associated with AIA compliance.
Impact and timelines
In addition to the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR), medical device manufacturers of AI-enabled and ML-enabled devices will need to comply with the AIA. Due to the nature of medical devices and IVDs, it is envisioned that the majority of AI/ML-enabled devices will fall into the high-risk category. While it is planned for these devices to undergo conformity assessment under the MDR or IVDR, the practicality is yet to be understood due to the specificities of each regulation.
Table 1 outlines the timeline and actions for compliance with the AIA. Medical device and IVD manufacturers subject to the AIA will have a maximum three-year period to comply with the regulation, unless a significant change to the AI system is made which will trigger compliance obligations sooner.
Timeline | Actions |
March 2024 | Adoption European Parliament Plenary vote and adoption of the AIA. |
Q2/Q3 2024 | Date of Publication Formal adoption and publication in OJEU. |
Date of publication in OJEU + 20 days | Entry into force The AIA enters into force. |
Entry into force + 6 months |
Prohibitions on unacceptable risk AI systems General provisions apply. Provisions on prohibited AI systems apply. |
Entry into force + 9 months |
Codes of practice
|
Entry into force + 12 months |
GPAI rules apply
|
Entry into force + 18 months |
Post-market monitoring
|
Entry into force + 24 months |
Date of Application
|
Entry into force + 36 months |
|
EU Artificial Intelligence Act Timelines and Penalties | Emergo by UL
The European Artificial Intelligence Act: Penalties and Timelines
This is the third in our series of regulatory updates on the EU Artificial Intelligence Act (AIA). In this article, we examine relevant timelines and penalties for medical device manufacturers in the EU.
www.emergobyul.com